

January 8, 2018

Elyse Bourque appointed Vice President, Medicinal Chemistry at Chaperone

Chaperone Therapeutics, Inc. is pleased to announce the appointment of Elyse Bourque, Ph.D., as the Vice President of Medicinal Chemistry. Dr. Bourque has over 15 years of experience in drug discovery and development. As Associate Scientific Director at Genzyme she led medicinal chemistry programs for the rare diseases portfolio and contributed to discovery and development of venglustat, a CNS-penetrant compound currently in clinical trials for Fabry disease and Parkinson's disease. Elyse received her Ph. D. in Organic Chemistry from the University of Sherbrooke, Canada, and completed a Postdoctoral Fellowship at the University of Leeds, United Kingdom. "We are delighted to welcome Elyse to Chaperone's management team" says Kalpana Merchant, the President and CEO of Chaperone Therapeutics, Inc. "Elyse's experience and success at designing CNS therapies is a perfect match for Chaperone's drug development programs aiming to slow the progression of neurodegenerative diseases caused by protein misfolding."